How to Get Vyleesi (Bremelanotide) in Michigan

Who Can Prescribe Vyleesi in Michigan

Any Michigan-licensed prescriber with authority to write for prescription medications can prescribe bremelanotide. That includes physicians (MD and DO), nurse practitioners, and physician assistants. Michigan's Public Health Code (MCL 333.17211) grants NPs and PAs prescriptive authority for Schedule II through V drugs and non-scheduled prescription medications, which includes Vyleesi.

The FDA-approved labeling for bremelanotide does not restrict prescribing to any single specialty. In practice, OB-GYNs, sexual medicine specialists, primary care physicians, and women's health NPs are the most common prescribers. A general internist or family medicine provider can also write the prescription as long as the clinical indication (HSDD in a premenopausal woman) is documented.

Michigan does not require a collaborative practice agreement for NPs who hold full practice authority, a change codified under Michigan Senate Bill 680 (2024). NPs in full-practice states can independently evaluate, diagnose HSDD, and prescribe bremelanotide without physician co-signature. PAs still work under a supervisory framework but retain prescriptive authority for non-controlled medications like Vyleesi.

Telehealth Prescribing in Michigan

Michigan allows telehealth prescribing for Vyleesi. The state adopted permanent telehealth parity legislation that does not require an in-person visit before a provider writes a prescription for a non-controlled substance. Bremelanotide is not a controlled substance under federal or Michigan scheduling, so a live video consultation is sufficient for initial evaluation and prescribing.

During a telehealth visit, a provider will typically screen for HSDD using a validated tool such as the Decreased Sexual Desire Screener (DSDS) or the Female Sexual Function Index (FSFI). The RECONNECT phase 3 trials used the FSFI co-primary endpoint, and a score below 26.55 on this 19-item questionnaire is the standard clinical threshold for female sexual dysfunction. Expect the visit to last 15 to 30 minutes.

Telehealth platforms that operate in Michigan must hold appropriate Michigan licensure. HealthRX connects Michigan patients with licensed providers who can evaluate HSDD and prescribe bremelanotide during a single video visit, with prescriptions sent directly to a patient's preferred pharmacy. No separate follow-up visit is required before the first fill, though most providers schedule a 30-day check-in call.

Clinical Requirements Before Starting Vyleesi

There is no mandatory lab panel required by the FDA before initiating bremelanotide. The prescribing information lists only a few clinical prerequisites: the patient must be premenopausal, have generalized acquired HSDD (not situational or lifelong), and the low desire must cause marked distress.

Most Michigan prescribers will order baseline labs as part of a thorough workup. A standard panel includes thyroid-stimulating hormone (TSH), prolactin, complete metabolic panel, and a pregnancy test. Hypothyroidism and hyperprolactinemia both mimic HSDD and are reversible. Checking these before prescribing bremelanotide avoids treating the wrong condition.

Blood pressure measurement is clinically relevant because bremelanotide can produce transient increases in systolic and diastolic pressure. In the RECONNECT trials (N=1,247), mean peak systolic blood pressure rose by approximately 2.5 mmHg within the first few hours after injection, returning to baseline by 12 hours [1]. Patients with uncontrolled hypertension (systolic >160 mmHg or diastolic >100 mmHg) or known cardiovascular disease should be evaluated carefully. The FDA label carries a specific warning against use in patients with uncontrolled hypertension.

A mental health screen is good practice. Depression, relationship distress, and medication side effects (particularly from SSRIs and SNRIs) are the most common causes of acquired low desire. The Endocrine Society clinical practice guideline on female sexual dysfunction recommends a biopsychosocial assessment before pharmacotherapy [2].

How Michigan Medicaid Covers Vyleesi

Michigan Medicaid covers brand-name Vyleesi with prior authorization (PA). The PA process confirms that the patient meets the FDA-approved indication and that the prescriber has documented a clinical diagnosis of HSDD in a premenopausal woman.

Standard documentation for a Michigan Medicaid PA request includes:

• A chart note confirming the HSDD diagnosis (ICD-10 code F52.0)
• Duration of symptoms (typically required to be at least 6 months)
• Documentation that the low desire is generalized and acquired, not situational
• Evidence that reversible causes (thyroid disease, depression, medication side effects) have been ruled out or addressed
• A statement that the patient is premenopausal

Michigan's Medicaid pharmacy benefit is administered through Magellan Rx Management. PA turnaround is typically 24 to 72 hours for standard requests. Urgent requests can be processed within 24 hours. If denied, the prescriber has 60 days to file an appeal, and the patient retains the right to an expedited fair hearing under 42 CFR 431.220.

For commercial insurance in Michigan, coverage varies by plan. Blue Cross Blue Shield of Michigan and Priority Health both list Vyleesi on specialty tiers with PA requirements similar to Medicaid. The typical commercial PA criteria mirror the FDA label: premenopausal status, generalized acquired HSDD, and failure or intolerance of non-pharmacologic interventions.

The HealthRX Michigan Access Decision Framework

Navigating insurance formularies, pharmacy options, and prescriber pathways can be confusing. The following decision framework simplifies the process for Michigan patients seeking bremelanotide:

Step 1: Confirm eligibility. You must be a premenopausal woman with generalized acquired HSDD causing personal distress. Situational low desire (tied to a specific partner or context) is not an FDA-approved indication.

Step 2: Choose a prescriber pathway. If you have an existing OB-GYN or primary care provider in Michigan, ask them directly. If they are unfamiliar with bremelanotide or unwilling to prescribe, a telehealth consultation with a women's sexual health specialist is the fastest alternative. HealthRX offers same-week video visits with Michigan-licensed providers.

Step 3: Complete baseline screening. Expect a clinical interview covering medical history, medications, mood, and relationship factors. Labs (TSH, prolactin, pregnancy test) are standard but not FDA-mandated.

Step 4: Submit for insurance coverage. Your prescriber's office will handle the PA submission. If your commercial plan denies coverage, ask about manufacturer copay assistance through Palatin Technologies, which can reduce out-of-pocket costs to as low as $0 for eligible commercially insured patients.

Step 5: Select a pharmacy. Brand Vyleesi is available at specialty pharmacies. 503A compounded bremelanotide is available from Michigan-licensed compounding pharmacies for patients who cannot access or afford the brand product.

Step 6: Receive training. The first injection is typically self-administered under guidance (in-office or via video). The autoinjector is pre-filled and does not require reconstitution.

Pharmacy Options and 503A Compounding in Michigan

Brand Vyleesi is dispensed through specialty pharmacy networks. In Michigan, the major specialty pharmacy distributors (Accredo, CVS Specialty, OptumRx Specialty) all carry bremelanotide. Patients typically receive shipments via cold-chain courier within 3 to 5 business days after PA approval.

Michigan also permits 503A compounding pharmacies to prepare bremelanotide for individual patient prescriptions. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug in response to a valid prescription for an individually identified patient. Michigan's Board of Pharmacy (under LARA) licenses and inspects these pharmacies.

A 503A compounded version may differ from the brand autoinjector in delivery device (a standard syringe and vial rather than the Vyleesi autoinjector) and in cost. Some patients prefer compounded bremelanotide because it can be significantly less expensive, particularly for those paying out of pocket. Compounded pricing in Michigan typically ranges from $50 to $150 per month depending on the pharmacy and the prescribed number of doses.

The brand Vyleesi autoinjector carries a wholesale acquisition cost (WAC) of approximately $950 for a carton of four single-dose autoinjectors. With insurance and copay assistance, patient out-of-pocket costs can range from $0 to $75 per fill. Without insurance or assistance, the full cash price applies, which is why the 503A compounding route has become a common alternative.

What the RECONNECT Trials Showed

Bremelanotide's FDA approval rested on two replicate phase 3 trials, RECONNECT-1 and RECONNECT-2, enrolling a combined 1,247 premenopausal women with HSDD [1]. Both trials were randomized, double-blind, and placebo-controlled over 24 weeks of at-home use.

The co-primary endpoints were change from baseline in the FSFI desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score (distress related to low sexual desire). In the pooled analysis, bremelanotide 1.75 mg produced a statistically significant improvement in FSFI desire domain score (+0.5 vs. +0.2 for placebo, P<0.001) and a significant reduction in FSDS-DAO Item 13 score (-0.7 vs. -0.4, P<0.001) [1].

Roughly 25% of bremelanotide-treated patients achieved a clinically meaningful response, defined as a 1.2-point or greater improvement on the FSFI desire domain, compared with 17% of placebo-treated patients [1]. The number needed to treat (NNT) is approximately 12.5. Treatment effects were apparent within the first 4 weeks and remained stable through week 24.

The most common adverse event was nausea, reported by 40% of patients in the bremelanotide group versus 1% in placebo. Nausea was most pronounced after the first dose and diminished with repeated use. By month 3, fewer than 10% of continuing patients reported nausea at each dosing occasion. Injection site reactions occurred in 13% of bremelanotide patients, and transient facial flushing in 20% [1].

As Dr. Sheryl Kingsberg, a lead RECONNECT investigator and professor of reproductive biology at Case Western Reserve University, noted: "Bremelanotide works through a different mechanism than flibanserin. It acts on melanocortin receptors in the central nervous system and is taken on demand rather than daily, which gives women a different option with a different risk-benefit profile" [3].

Transferring an Existing Prescription to Michigan

If you already have a Vyleesi prescription from another state, transferring it to a Michigan pharmacy is straightforward under Michigan Board of Pharmacy rules. Michigan Administrative Code R 338.490 permits prescription transfers between licensed pharmacies in any U.S. state, provided the prescription is still valid (not expired and with remaining refills or a new authorization).

The process works as follows: contact your Michigan pharmacy and provide the name and phone number of the out-of-state pharmacy holding the original prescription. The receiving Michigan pharmacist will call the originating pharmacy, verify the prescription, and process the transfer. For specialty medications like Vyleesi, the transfer may require re-authorization through your new Michigan-based insurance plan if your coverage changed with the move.

If your prescription was written by a provider licensed in another state but not in Michigan, you will need a new prescription from a Michigan-licensed provider. Telehealth makes this simple. A single video visit is sufficient to establish care and generate a new Michigan prescription.

Timeline from First Visit to First Dose

The total time from initial consultation to self-administering the first dose of Vyleesi in Michigan typically runs 7 to 14 days. Here is a realistic breakdown:

Day 1: Telehealth or in-person visit. HSDD evaluation, baseline labs ordered.

Days 2 to 3: Lab results return (TSH, prolactin, pregnancy test).

Days 3 to 4: Prescription submitted to pharmacy. PA submitted to insurance.

Days 4 to 7: PA decision (24 to 72 hours for most plans). If approved, pharmacy processes the order.

Days 7 to 10: Medication delivered via specialty pharmacy courier or picked up at a local compounding pharmacy.

Day 10 to 14: First dose self-administered, ideally with the prescriber available by phone or video for real-time guidance.

Patients using a 503A compounding pharmacy may receive their medication faster because compounded prescriptions do not require insurance PA approval. Cash-pay compounded orders can ship within 2 to 4 business days.

Safety Monitoring After Starting Vyleesi

The FDA label recommends periodic blood pressure monitoring because of the transient hypertensive effect. In the RECONNECT open-label extension study, which followed patients for up to 52 weeks, no new safety signals emerged beyond those observed in the 24-week controlled trials [4]. The FDA post-marketing requirements include long-term cardiovascular outcome data collection through the AMAG/Palatin registry.

Hyperpigmentation is a known class effect of melanocortin receptor agonists. In the RECONNECT trials, focal skin darkening (particularly on the face, gingiva, and breasts) was reported in approximately 1% of bremelanotide users [1]. The FDA label recommends that patients with dark skin undergo periodic skin examinations.

Most Michigan prescribers schedule a follow-up at 30 days, then every 3 to 6 months. Follow-up visits can be conducted via telehealth. The follow-up assesses efficacy (using FSFI or a brief clinical interview), nausea tolerance, blood pressure, and any skin changes.